Bebi Therapeutics
Developing derivatives of a small molecule isolated from bacterial consortia from non-small cell lung cancer patients that causes immune checkpoint inhibitor non-responders to become responsive to immune checkpoint inhibitor therapies Non-confidential slide deck available upon request Seeking seed funding
AquaLung
ALT-100 mAb inhibits inflammation and fibrosis Phase 2 clinical study (Acute Respiratory Distress) IND (Q4 2024) for lung fibrosis and pulmonary hypertension